

**WYETH**  
**WORLDWIDE NET REVENUE BY PRODUCT**  
**THREE MONTHS ENDED DECEMBER 31, 2008**  
(000's)  
(UNAUDITED)

	DOMESTIC				INTERNATIONAL						TOTAL					
	4TH QTR 2008	4TH QTR 2007	DOLLAR CHANGE	PERCENT CHANGE	4TH QTR 2008	4TH QTR 2007	DOLLAR CHANGE	PERCENT CHANGE	C\$ CHANGE	C\$ % CHANGE	4TH QTR 2008	4TH QTR 2007	DOLLAR CHANGE	PERCENT CHANGE	C\$ CHANGE	C\$ % CHANGE
<i>Wyeth Pharmaceuticals</i>																
EFFEXOR	\$ 662,965	\$ 645,579	\$ 17,386	2.7%	\$ 238,618	\$ 322,611	\$ (83,993)	-26.0%	\$ (42,282)	-13.1%	\$ 901,583	\$ 968,190	\$ (66,607)	-6.9%	\$ (24,896)	-2.6%
PREVNAR	272,191	256,462	15,729	6.1%	329,933	299,199	30,734	10.3%	82,658	27.6%	602,124	555,661	46,463	8.4%	98,387	17.7%
ENBREL OUTSIDE U.S. & CANADA	-	-	-	N/A	597,789	564,976	32,813	5.8%	124,562	22.0%	597,789	564,976	32,813	5.8%	124,562	22.0%
ENBREL ALLIANCE REVENUE	284,813	248,107	36,706	14.8%	16,272	17,733	(1,461)	-8.2%	(1,273)	-7.2%	301,085	265,840	35,245	13.3%	35,433	13.3%
NUTRITIONALS	1,131	721	410	56.9%	384,072	391,944	(7,872)	-2.0%	25,626	6.5%	385,203	392,665	(7,462)	-1.9%	26,036	6.6%
ZOSYN/AZOCIN	188,451	146,668	41,783	28.5%	109,714	145,324	(35,610)	-24.5%	(18,674)	-12.8%	298,165	291,992	6,173	2.1%	23,109	7.9%
PREMARIN FAMILY	237,877	233,829	4,048	1.7%	23,910	30,390	(6,480)	-21.3%	(1,499)	-4.9%	261,787	264,219	(2,432)	-0.9%	2,549	1.0%
PROTONIX RX	115,511	461,571	(346,060)	-75.0%	-	-	-	N/A	-	N/A	115,511	461,571	(346,060)	-75.0%	(346,060)	-75.0%
PROTONIX GENERIC	70,190	-	70,190	N/A	-	-	-	N/A	-	N/A	70,190	-	70,190	N/A	70,190	N/A
BENEFIX	67,340	57,508	9,832	17.1%	66,355	71,389	(5,034)	-7.1%	5,478	7.7%	133,695	128,897	4,798	3.7%	15,310	11.9%
BMP-2	80,983	72,088	8,895	12.3%	3,265	2,387	878	36.8%	1,309	54.8%	84,248	74,475	9,773	13.1%	10,204	13.7%
CONTRACEPTIVES (including LYBREL)	7,624	13,262	(5,638)	-42.5%	73,789	90,637	(16,848)	-18.6%	(7,597)	-8.4%	81,413	103,899	(22,486)	-21.6%	(13,235)	-12.7%
RAPAMUNE	49,690	49,164	526	1.1%	40,164	50,385	(10,221)	-20.3%	(3,129)	-6.2%	89,854	99,549	(9,695)	-9.7%	(2,603)	-2.6%
REFACTO/XYNTHA	18,397	17,657	740	4.2%	59,758	69,597	(9,839)	-14.1%	(1,174)	-1.7%	78,155	87,254	(9,099)	-10.4%	(434)	-0.5%
TYGACIL	36,128	28,011	8,117	29.0%	24,034	12,905	11,129	86.2%	13,720	106.3%	60,162	40,916	19,246	47.0%	21,837	53.4%
TORISEL	21,630	15,483	6,147	39.7%	13,143	562	12,581	N/A	12,270	N/A	34,773	16,045	18,728	116.7%	18,417	114.8%
PRISTIQ	32,497	-	32,497	N/A	-	-	-	N/A	-	N/A	32,497	-	32,497	N/A	32,497	N/A
<i>subtotal</i>	<i>2,147,418</i>	<i>2,246,110</i>	<i>(98,692)</i>	<i>-4.4%</i>	<i>1,980,816</i>	<i>2,070,039</i>	<i>(89,223)</i>	<i>-4.3%</i>	<i>189,995</i>	<i>9.2%</i>	<i>4,128,234</i>	<i>4,316,149</i>	<i>(187,915)</i>	<i>-4.4%</i>	<i>91,303</i>	<i>2.1%</i>
<b>OTHER PHARMACEUTICALS</b>	34,522	94,991	(60,469)	-63.7%	246,430	313,247	(66,817)	-21.3%	(58,557)	-18.7%	280,952	408,238	(127,286)	-31.2%	(119,026)	-29.2%
<b>TOTAL WYETH PHARMACEUTICALS</b>	<b>\$ 2,181,940</b>	<b>\$ 2,341,101</b>	<b>\$ (159,161)</b>	<b>-6.8%</b>	<b>\$ 2,227,246</b>	<b>\$ 2,383,286</b>	<b>\$ (156,040)</b>	<b>-6.5%</b>	<b>\$ 131,438</b>	<b>5.5%</b>	<b>\$ 4,409,186</b>	<b>\$ 4,724,387</b>	<b>\$ (315,201)</b>	<b>-6.7%</b>	<b>\$ (27,723)</b>	<b>-0.6%</b>
<b>TOTAL FORT DODGE</b>	<b>\$ 96,760</b>	<b>\$ 100,685</b>	<b>\$ (3,925)</b>	<b>-3.9%</b>	<b>\$ 140,108</b>	<b>\$ 151,907</b>	<b>\$ (11,799)</b>	<b>-7.8%</b>	<b>\$ 9,432</b>	<b>6.2%</b>	<b>\$ 236,868</b>	<b>\$ 252,592</b>	<b>\$ (15,724)</b>	<b>-6.2%</b>	<b>\$ 5,507</b>	<b>2.2%</b>
<i>Wyeth Consumer Healthcare</i>																
CENTRUM	\$ 83,988	\$ 102,781	\$ (18,793)	-18.3%	\$ 85,881	\$ 101,281	\$ (15,400)	-15.2%	\$ (2,919)	-2.9%	\$ 169,869	\$ 204,062	\$ (34,193)	-16.8%	(21,712)	-10.6%
ADVIL	127,776	139,670	(11,894)	-8.5%	43,090	46,724	(3,634)	-7.8%	4,448	9.5%	170,866	186,394	(15,528)	-8.3%	(7,446)	-4.0%
CALTRATE	18,806	19,756	(950)	-4.8%	42,120	40,917	1,203	2.9%	3,816	9.3%	60,926	60,673	253	0.4%	2,866	4.7%
ROBITUSSIN	66,720	55,606	11,114	20.0%	14,276	16,808	(2,532)	-15.1%	(568)	-3.4%	80,996	72,414	8,582	11.9%	10,546	14.6%
CHAPSTICK	47,430	50,631	(3,201)	-6.3%	6,044	8,995	(2,951)	-32.8%	(1,524)	-16.9%	53,474	59,626	(6,152)	-10.3%	(4,725)	-7.9%
PREPARATION H	21,945	22,528	(583)	-2.6%	4,445	5,769	(1,324)	-23.0%	(597)	-10.3%	26,390	28,297	(1,907)	-6.7%	(1,180)	-4.2%
ADVIL COLD & SINUS	10,522	13,190	(2,668)	-20.2%	10,879	12,665	(1,786)	-14.1%	314	2.5%	21,401	25,855	(4,454)	-17.2%	(2,354)	-9.1%
THERMACARE	15,924	-	15,924	N/A	4,236	-	4,236	N/A	5,044	N/A	20,160	-	20,160	N/A	20,968	N/A
OTHER	23,067	56,134	(33,067)	-58.9%	75,116	93,092	(17,976)	-19.3%	(5,181)	-5.6%	98,183	149,226	(51,043)	-34.2%	(38,248)	-25.6%
<b>TOTAL CONSUMER HEALTHCARE</b>	<b>\$ 416,178</b>	<b>\$ 460,296</b>	<b>\$ (44,118)</b>	<b>-9.6%</b>	<b>\$ 286,087</b>	<b>\$ 326,251</b>	<b>\$ (40,164)</b>	<b>-12.3%</b>	<b>\$ 2,833</b>	<b>0.9%</b>	<b>\$ 702,265</b>	<b>\$ 786,547</b>	<b>\$ (84,282)</b>	<b>-10.7%</b>	<b>\$ (41,285)</b>	<b>-5.2%</b>
<i>Wyeth</i>																
<b>TOTAL PHARMACEUTICALS</b>	<b>\$ 2,181,940</b>	<b>\$ 2,341,101</b>	<b>\$ (159,161)</b>	<b>-6.8%</b>	<b>\$ 2,227,246</b>	<b>\$ 2,383,286</b>	<b>\$ (156,040)</b>	<b>-6.5%</b>	<b>\$ 131,438</b>	<b>5.5%</b>	<b>\$ 4,409,186</b>	<b>\$ 4,724,387</b>	<b>\$ (315,201)</b>	<b>-6.7%</b>	<b>\$ (27,723)</b>	<b>-0.6%</b>
<b>TOTAL FORT DODGE</b>	<b>96,760</b>	<b>100,685</b>	<b>(3,925)</b>	<b>-3.9%</b>	<b>140,108</b>	<b>151,907</b>	<b>(11,799)</b>	<b>-7.8%</b>	<b>9,432</b>	<b>6.2%</b>	<b>236,868</b>	<b>252,592</b>	<b>(15,724)</b>	<b>-6.2%</b>	<b>5,507</b>	<b>2.2%</b>
<b>TOTAL CONSUMER HEALTHCARE</b>	<b>416,178</b>	<b>460,296</b>	<b>(44,118)</b>	<b>-9.6%</b>	<b>286,087</b>	<b>326,251</b>	<b>(40,164)</b>	<b>-12.3%</b>	<b>2,833</b>	<b>0.9%</b>	<b>702,265</b>	<b>786,547</b>	<b>(84,282)</b>	<b>-10.7%</b>	<b>(41,285)</b>	<b>-5.2%</b>
<b>TOTAL WYETH</b>	<b>\$ 2,694,878</b>	<b>\$ 2,902,082</b>	<b>\$ (207,204)</b>	<b>-7.1%</b>	<b>\$ 2,653,441</b>	<b>\$ 2,861,444</b>	<b>\$ (208,003)</b>	<b>-7.3%</b>	<b>\$ 143,703</b>	<b>5.0%</b>	<b>\$ 5,348,319</b>	<b>\$ 5,763,526</b>	<b>\$ (415,207)</b>	<b>-7.2%</b>	<b>\$ (63,501)</b>	<b>-1.1%</b>
<i>Domestic / Int'l Percentage of Total</i>	<b>50%</b>	<b>50%</b>			<b>50%</b>	<b>50%</b>					<b>100%</b>	<b>100%</b>				

**Notes:**

- Certain reclassification adjustments have been made in 2007 in order to conform to the 2008 presentation.
- Alliance revenue attributable to Altace and the Cypher Stent have been included in Other Pharmaceuticals.

WYETH  
WORLDWIDE NET REVENUE BY PRODUCT  
TWELVE MONTHS ENDED DECEMBER 31, 2008  
(000's)  
(UNAUDITED)

	DOMESTIC				INTERNATIONAL						TOTAL					
	YTD 2008	YTD 2007	DOLLAR CHANGE	PERCENT CHANGE	YTD 2008	YTD 2007	DOLLAR CHANGE	PERCENT CHANGE	C\$ CHANGE	C\$ % CHANGE	YTD 2008	YTD 2007	DOLLAR CHANGE	PERCENT CHANGE	C\$ CHANGE	C\$ % CHANGE
<i>Wyeth Pharmaceuticals</i>																
EFFEXOR	\$ 2,686,868	\$ 2,577,062	\$ 109,806	4.3%	1,240,988	1,216,842	\$ 24,146	2.0%	\$ (19,893)	-1.6%	\$ 3,927,856	\$ 3,793,904	\$ 133,952	3.5%	\$ 89,913	2.4%
PREVNAR	1,180,062	1,140,462	39,600	3.5%	1,535,445	1,298,594	236,851	18.2%	199,441	15.4%	2,715,507	2,439,056	276,451	11.3%	239,041	9.8%
ENBREL OUTSIDE U.S. & CANADA	-	-	-	N/A	2,592,918	2,044,628	548,290	26.8%	490,916	24.0%	2,592,918	2,044,628	548,290	26.8%	490,916	24.0%
ENBREL ALLIANCE REVENUE	1,134,741	940,614	194,127	20.6%	69,931	59,147	10,784	18.2%	(2,572)	-4.3%	1,204,672	999,761	204,911	20.5%	191,555	19.2%
NUTRITIONALS	4,352	3,514	838	23.8%	1,629,549	1,439,520	190,029	13.2%	167,413	11.6%	1,633,901	1,443,034	190,867	13.2%	168,251	11.7%
ZOSYN/TAZOCIN	701,105	575,775	125,330	21.8%	562,931	561,418	1,513	0.3%	(11,537)	-2.1%	1,264,036	1,137,193	126,843	11.2%	113,793	10.0%
PREMARIN FAMILY	965,897	948,668	17,229	1.8%	104,504	106,669	(2,165)	-2.0%	(202)	-0.2%	1,070,401	1,055,337	15,064	1.4%	17,027	1.6%
PROTONIX RX	394,871	1,911,247	(1,516,376)	-79.3%	-	-	-	N/A	-	N/A	394,871	1,911,247	(1,516,376)	-79.3%	(1,516,376)	-79.3%
PROTONIX GENERIC	411,569	-	411,569	N/A	-	-	-	N/A	-	N/A	411,569	-	411,569	N/A	411,569	N/A
BENEFIX	262,818	273,541	(10,723)	-3.9%	324,044	159,105	164,939	103.7%	172,590	108.5%	586,862	432,646	154,216	35.6%	161,867	37.4%
BMP-2	376,426	350,572	25,854	7.4%	13,195	8,314	4,881	58.7%	4,449	53.5%	389,621	358,886	30,735	8.6%	30,303	8.4%
CONTRACEPTIVES (including LYBREL)	42,459	50,740	(8,281)	-16.3%	343,510	383,114	(39,604)	-10.3%	(54,852)	-14.3%	385,969	433,854	(47,885)	-11.0%	(63,133)	-14.6%
RAPAMUNE	190,876	189,134	1,742	0.9%	184,919	175,631	9,288	5.3%	4,977	2.8%	375,795	364,765	11,030	3.0%	6,719	1.8%
REFACTO/XYNTHA	73,677	73,428	249	0.3%	289,577	261,429	28,148	10.8%	13,188	5.0%	363,254	334,857	28,397	8.5%	13,437	4.0%
TYGACIL	132,531	97,277	35,254	36.2%	83,653	40,629	43,024	105.9%	41,302	101.7%	216,184	137,906	78,278	56.8%	76,556	55.5%
TRISEL	82,292	26,028	56,264	216.2%	39,825	565	39,260	N/A	38,944	N/A	122,117	26,593	95,524	359.2%	95,208	358.0%
PRISTIQ	66,512	-	66,512	N/A	-	-	-	N/A	-	N/A	66,512	-	66,512	N/A	66,512	N/A
<i>subtotal</i>	<i>8,707,056</i>	<i>9,158,062</i>	<i>(451,006)</i>	<i>-4.9%</i>	<i>9,014,989</i>	<i>7,755,605</i>	<i>1,259,384</i>	<i>16.2%</i>	<i>1,044,164</i>	<i>13.5%</i>	<i>17,722,045</i>	<i>16,913,667</i>	<i>808,378</i>	<i>4.8%</i>	<i>593,158</i>	<i>3.5%</i>
OTHER PHARMACEUTICALS	209,027	525,988	(316,961)	-60.3%	1,094,358	1,182,328	(87,970)	-7.4%	(124,068)	-10.5%	1,303,385	1,708,316	(404,931)	-23.7%	(441,029)	-25.8%
<b>TOTAL WYETH PHARMACEUTICALS</b>	<b>\$ 8,916,083</b>	<b>\$ 9,684,050</b>	<b>\$ (767,967)</b>	<b>-7.9%</b>	<b>\$ 10,109,347</b>	<b>\$ 8,937,933</b>	<b>\$ 1,171,414</b>	<b>13.1%</b>	<b>\$ 920,096</b>	<b>10.3%</b>	<b>\$ 19,025,430</b>	<b>\$ 18,621,983</b>	<b>\$ 403,447</b>	<b>2.2%</b>	<b>\$ 152,129</b>	<b>0.8%</b>
<b>TOTAL FORT DODGE</b>	<b>\$ 406,140</b>	<b>\$ 446,210</b>	<b>\$ (40,070)</b>	<b>-9.0%</b>	<b>\$ 681,782</b>	<b>\$ 595,521</b>	<b>\$ 86,261</b>	<b>14.5%</b>	<b>\$ 71,246</b>	<b>12.0%</b>	<b>\$ 1,087,922</b>	<b>\$ 1,041,731</b>	<b>\$ 46,191</b>	<b>4.4%</b>	<b>\$ 31,176</b>	<b>3.0%</b>
<i>Wyeth Consumer Healthcare</i>																
CENTRUM	\$ 323,666	\$ 332,842	\$ (9,176)	-2.8%	404,299	\$ 372,053	\$ 32,246	8.7%	\$ 18,754	5.0%	\$ 727,965	\$ 704,895	\$ 23,070	3.3%	9,578	1.4%
ADVIL	483,915	513,812	(29,897)	-5.8%	189,354	170,287	19,067	11.2%	15,070	8.8%	673,269	684,099	(10,830)	-1.6%	(14,827)	-2.2%
CALTRATE	75,309	73,030	2,279	3.1%	173,899	152,841	21,058	13.8%	13,083	8.6%	249,208	225,871	23,337	10.3%	15,362	6.8%
ROBITUSSIN	139,678	166,090	(26,412)	-15.9%	59,041	54,251	4,790	8.8%	4,142	7.6%	198,719	220,341	(21,622)	-9.8%	(22,270)	-10.1%
CHAPSTICK	109,569	112,652	(3,083)	-2.7%	28,004	27,095	909	3.4%	2,369	8.7%	137,573	139,747	(2,174)	-1.6%	(714)	-0.5%
PREPARATION H	87,308	85,454	1,854	2.2%	24,427	24,258	169	0.7%	(650)	-2.7%	111,735	109,712	2,023	1.8%	1,204	1.1%
ADVIL COLD & SINUS	29,948	33,039	(3,091)	-9.4%	41,897	40,635	1,262	3.1%	1,220	3.0%	71,845	73,674	(1,829)	-2.5%	(1,871)	-2.5%
THERMACARE	20,510	-	20,510	N/A	5,960	-	5,960	N/A	6,841	N/A	26,470	-	26,470	N/A	27,351	N/A
OTHER	122,498	190,505	(68,007)	-35.7%	401,274	387,240	14,034	3.6%	1,944	0.5%	523,772	577,745	(53,973)	-9.3%	(66,063)	-11.4%
<b>TOTAL CONSUMER HEALTHCARE</b>	<b>\$ 1,392,401</b>	<b>\$ 1,507,424</b>	<b>\$ (115,023)</b>	<b>-7.6%</b>	<b>\$ 1,328,155</b>	<b>\$ 1,228,660</b>	<b>\$ 99,495</b>	<b>8.1%</b>	<b>\$ 62,773</b>	<b>5.1%</b>	<b>\$ 2,720,556</b>	<b>\$ 2,736,084</b>	<b>\$ (15,528)</b>	<b>-0.6%</b>	<b>\$ (52,250)</b>	<b>-1.9%</b>
<i>Wyeth</i>																
<b>TOTAL PHARMACEUTICALS</b>	<b>\$ 8,916,083</b>	<b>\$ 9,684,050</b>	<b>\$ (767,967)</b>	<b>-7.9%</b>	<b>\$ 10,109,347</b>	<b>\$ 8,937,933</b>	<b>\$ 1,171,414</b>	<b>13.1%</b>	<b>\$ 920,096</b>	<b>10.3%</b>	<b>\$ 19,025,430</b>	<b>\$ 18,621,983</b>	<b>\$ 403,447</b>	<b>2.2%</b>	<b>\$ 152,129</b>	<b>0.8%</b>
<b>TOTAL FORT DODGE</b>	<b>406,140</b>	<b>446,210</b>	<b>(40,070)</b>	<b>-9.0%</b>	<b>681,782</b>	<b>595,521</b>	<b>86,261</b>	<b>14.5%</b>	<b>71,246</b>	<b>12.0%</b>	<b>1,087,922</b>	<b>1,041,731</b>	<b>46,191</b>	<b>4.4%</b>	<b>31,176</b>	<b>3.0%</b>
<b>TOTAL CONSUMER HEALTHCARE</b>	<b>1,392,401</b>	<b>1,507,424</b>	<b>(115,023)</b>	<b>-7.6%</b>	<b>1,328,155</b>	<b>1,228,660</b>	<b>99,495</b>	<b>8.1%</b>	<b>62,773</b>	<b>5.1%</b>	<b>2,720,556</b>	<b>2,736,084</b>	<b>(15,528)</b>	<b>-0.6%</b>	<b>(52,250)</b>	<b>-1.9%</b>
<b>TOTAL WYETH</b>	<b>\$ 10,714,624</b>	<b>\$ 11,637,684</b>	<b>\$ (923,060)</b>	<b>-7.9%</b>	<b>\$ 12,119,284</b>	<b>\$ 10,762,114</b>	<b>\$ 1,357,170</b>	<b>12.6%</b>	<b>\$ 1,054,115</b>	<b>9.8%</b>	<b>\$ 22,833,908</b>	<b>\$ 22,399,798</b>	<b>\$ 434,110</b>	<b>1.9%</b>	<b>\$ 131,055</b>	<b>0.6%</b>
<i>Domestic / Int'l Percentage of Total</i>	<i>47%</i>	<i>52%</i>			<i>53%</i>	<i>48%</i>					<i>100%</i>	<i>100%</i>				

**Notes:**  
- Certain reclassification adjustments have been made in 2007 in order to conform to the 2008 presentation.  
- Alliance revenue attributable to Altace and the Cypher Stent have been included in Other Pharmaceuticals.